drugset / Trial / NCT00865891
A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
The purpose of this study is to compare the relative bioavailability of Nifedipine ER tablets 60 mg by Abrica Pharmaceuticals LLLP with that of ADALAT® CC Extended Release Tablets 60 mg by Bayer Pharmaceuticals Corporation, Bayer HealthCare following a single oral dose (1 x 60 mg tablet) in healthy adult volunteers under fasting conditions.
Timeline
- Start
- 2005-07
- Primary completion
- 2005-07
- Completion
- 2005-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nifedipine | Other / unclassified | 60 mg | Oral |
Indications
No indication recorded.